XKRX229000
Market cap12mUSD
Dec 24, Last price
1,313.00KRW
Name
Gencurix Inc
Chart & Performance
P/E
—
P/S
6.69
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.85%
Rev. gr., 5y
59.45%
Revenues
2.60b
+1.60%
Net income
-19.26b
L-21.70%
CFO
-10.88b
L+4.06%
Earnings
Mar 18, 2025
Profile
Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 2,600,318 1.60% | 2,559,487 -16.00% | 3,046,946 93.83% | ||||||
Cost of revenue | 8,540,396 | 8,259,119 | 11,631,155 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (5,940,079) | (5,699,632) | (8,584,209) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (155,315) | (650) | (585) | ||||||
Tax Rate | |||||||||
NOPAT | (5,784,763) | (5,698,982) | (8,583,624) | ||||||
Net income | (19,260,021) -21.70% | (24,596,962) -29.05% | (34,670,023) -204.72% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 25,001,821 | 9,169,431 | |||||||
BB yield | -34.00% | -7.00% | |||||||
| Debt | |||||||||
Debt current | 12,219,659 | 4,236,237 | 377,106 | ||||||
Long-term debt | 4,879,163 | 3,999,030 | 475,836 | ||||||
Deferred revenue | 6 | ||||||||
Other long-term liabilities | 1,142,900 | 1,847,638 | 810,280 | ||||||
Net debt | 641,605 | (12,314,896) | (47,350,555) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (10,876,925) | (10,452,261) | (8,366,163) | ||||||
CAPEX | (2,176,977) | (13,046,042) | (1,470,896) | ||||||
Cash from investing activities | (6,717,682) | (3,174,872) | (11,105,635) | ||||||
Cash from financing activities | 14,650,596 | 7,481,056 | 25,765,035 | ||||||
FCF | (19,323,812) | (4,316,656) | (8,949,496) | ||||||
| Balance | |||||||||
Cash | 11,269,693 | 5,858,157 | 21,963,730 | ||||||
Long term investments | 5,187,524 | 14,692,005 | 26,239,767 | ||||||
Excess cash | 16,327,201 | 20,422,188 | 48,051,149 | ||||||
Stockholders' equity | (80,182,479) | (61,918,161) | (35,356,259) | ||||||
Invested Capital | 110,236,523 | 77,525,242 | 67,824,040 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 11,821 | 7,430 | 7,319 | ||||||
Price | 6,220.00 -10.12% | 6,920.00 -61.34% | 17,900.00 8.48% | ||||||
Market cap | 73,529,008 43.01% | 51,415,593 -60.76% | 131,012,928 12.66% | ||||||
EV | 72,421,552 | 38,458,134 | 83,917,875 | ||||||
EBITDA | (4,549,485) | (4,784,514) | (8,152,215) | ||||||
EV/EBITDA | |||||||||
Interest | 810,725 | 478,246 | 278,206 | ||||||
Interest/NOPBT | |||||||||